While patients are in the process of receiving IV fluids, they will be kept on continuous cardiac and oxygenation monitoring. We believe it is highly unlikely that any subject will need any medical care during this study. However, let it be noted that there will be an attending and/or resident physician present at all times while patients are receiving treatment. Should any subject develop adverse effects as a result of our study, the physician will assess the patient and offer to register them in the emergency department. Any Serious Adverse Event (SAE) will be reported to the IRB within 5 days.